Fundraising September 15, 2024 – October 1, 2024 About fundraising

Novel first-in-class, fatty acid synthase inhibitor,...

Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1)

Loomba, Rohit, Rinella, Mary, Harrison, Stephen, Wong, Vincent Wai-Sun, Ratziu, Vlad, Mohseni, Rizwana, Lucas, Kathryn Jean, Perry, Robert G., Rahmini, Robert, Trotter, James F., Gutierrez, Julio, Gri
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
73
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(20)30653-X
Date:
August, 2020
File:
PDF, 62 KB
2020
Conversion to is in progress
Conversion to is failed